Call us: +38 (067) 242 82 22

Amyotrophic lateral sclerosis


It is possible to slow down the progression of amyotrophic lateral sclerosis with cell therapy.

Safe stem cells

Slowing down the development of ALS and improving the quality of life


Heading photo

Stem cell treatment of ALS

In amyotrophic lateral sclerosis (ALS), the central and peripheral motoneurons are destroyed. The main symptoms of the disease: disorders of motor activity; muscle weakness; atrophy.
Usually, lesions in ALS are generalized, even in the absence of clinical manifestations, electroneuromyography reveals degenerative changes. Patients develop paralysis of the upper and lower limbs; speech, swallowing, breathing, heartbeat dysfunction, etc.
Therapy is aimed at stopping the progression of the disease. Methods of treatment of ALS are still being studied. Popular in 2014, the Ice Bucket Challenge was created to raise funds for the study of ALS.
Our team is doing everything possible to make the symptoms of the disease milder. We propose the use of a combination of mesenchymal stem cells from adipose tissue (MSCs of adipose tissue) and multipotent stem cells derived from the nerve crest (HF NCSCs).
Therapy includes endolumbar, intravenous drip, and topical administration of cells. The injection should be repeated every six months.

Heading photo

ALS treatment at GOOD CELLS

Indications:
This treatment is indicated for patients over 18 y.o. with diagnosed amyotrophic lateral sclerosis.
Contraindications:
oncological diseases or their presence in the anamnesis for the last five years; pregnancy; mental disorders; alcohol and drug addiction.

Heading photo

Cell therapy program for slowing down ALS

Mesenchymal stem cells (MSCs) can differentiate into endoderm and ectoderm derivatives, including neurons and glial cells.Therefore, MSCs are constantly being studied as a potential tool for treating pathologies whose pharmacological treatment gives poor results. Such diseases include amyotrophic lateral sclerosis.
The following properties of MSCs have already been proven: immunomodulatory; anti-inflammatory; antiapoptotic; ability to stimulate neurogenesis and angiogenesis; homing — going to the affected areas of the body.
The cell therapy we offer can stop the development of ALS. Explicit results are observed on average six months after the introduction of MSCs.

Safe stem cells

The treatment process

  • 1. Consultation with a manager

    Contact our managers to help arrange a free online consultation with your doctor to confirm the diagnosis and details to make sure that this treatment is suited for you.

  • 2. Consultation with a doctor 

    A personal consultation with a doctor is an opportunity for you to find out all details of the program and get an individual prognosis. All the medical information you provide will be carefully reviewed so that you get the most effective treatment. The procedures take place in our clinical institutions in Kyiv, Ukraine.
    The course of the treatment is developed individually and lasts from 3 days.

  • 3. Checkup

    During the checkup, the doctor assesses your readiness for cell therapy. If the assessment is positive, biological materials are taken. Depending on your doctor's recommendations, you may be prescribed your own* or donor stem cells.

    * If you are prescribed the treatment with your own cells, you will have an ear punch biopsy performed under anesthesia in an operating room. The procedure lasts for 15 minutes. The punch depth is up to 4 mm, and the diameter is up to 3 mm.

  • 4. Preparation of the stem cell product

    OWN CELLSAfter the biomaterials are collected, our team of biotechnologists will prepare a therapeutic dose of stem cells. In our laboratory, we will select stem cells from your sample, grow the required number of cells, test them, then create a stem cell product for your treatment. Usually, the production takes up to 21 days.
    DONOR CELLSAccording to the doctor's prescription, the biotechnologist will select a ready-made and pre-tested sample of donor cells from our cryobank in the required quantity. In this case, cell injection can happen immediately after diagnosis and drug preparation.

  • 5. Start of treatment

    During the first visit, you will consult a doctor and have instrumental, clinical, and laboratory checkups. If the doctor needs to clarify the disease and its course, you may be prescribed needle electromyography or stimulation combined with a needle. If necessary, you may be offered additional MRIs.

    Based on the results of the checkup, the doctor may prescribe the drug therapy by intravenous infusion and intramuscular injection.

  • 6. Injection of the cellular product, the regeneration phase

    The doctor may prescribe endolumbar injection, intravenous cell therapy, and local injection of cells. It is recommended to repeat the injection once every 6 months.

  • 7. Medical report and reducing of the basic treatment

    You will be provided with a medical assessment report that states the diagnosis, the examination results (clinical, laboratory, and instrumental), the treatment process, and further recommendations. The doctor will examine you, select the necessary treatment, or adjust the one prescribed to you at the time of arrival at the clinic.

  • 8. Keeping in touch

    The results can be observed in 6 months after the treatment — you will see the improvement of the regenerative processes in the body.

    Throughout the program, you will have a personal manager who will ensure the best communication between you and the clinic. After treatment, our patients are advised to maintain contact with us. We'll ask you to fill out a questionnaire in 3 and 6 months after the treatment to evaluate the progress and answer all questions.

Safe stem cells

Scientific evidence

The study by Barczewska M. et al. showed that intrathecal administration of umbilical cord MSCs in patients with amyotrophic lateral sclerosis prolongs life expectancy mainly twice compared to patients who did not receive cell therapy (1183 days vs. 640 days, p = 0.002).
The incidence of deaths decreased by 70% in the group that received umbilical cord MSCs, compared to the control group. In 21 of 67 (31.3%) patients, the rate of ALSFRS-R decreased. In addition, the researchers identified the parameters by which cell therapy would be appropriate and bring good results: female gender and a good response to the first administration of MSCs. These conditions are strong predictors of better outcomes during subsequent treatment of umbilical cord MSCs.
The results of the publication can be found here:
Barczewska, M., Maksymowicz, S., Zdolińska-Malinowska, I. et al. Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study. Stem Cell Rev and Rep 16, 922–932, 2020. https://doi.org/10.1007/s12015-020-10016-7